116TH CONGRESS 1ST SESSION H.R. 2038

To allow State-based, market-oriented, prescription drug negotiations to lower pharmaceutical drug prices, to encourage competition, to increase consumer choice and access, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

April 2, 2019

Mr. MEADOWS introduced the following bill; which was referred to the Committee on the Judiciary

A BILL

- To allow State-based, market-oriented, prescription drug negotiations to lower pharmaceutical drug prices, to encourage competition, to increase consumer choice and access, and for other purposes.
 - 1 Be it enacted by the Senate and House of Representa-
 - 2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

- 4 This Act may be cited as the "State-Based, Market-
- 5 Oriented, Prescription Drug Negotiations Act of 2019".

 $\mathbf{2}$

2 SURER ISSUERS TO NEGOTIATE WHOLESALE
3 ACQUISITION PRICES OF PRESCRIPTION
4 DRUGS PURCHASED FROM DRUG MANUFAC5 TURERS.

6 It shall not be a violation of the antitrust laws for 7 one or more private health insurer issuers or their des-8 ignated agents to jointly negotiate wholesale acquisition 9 prices of a prescription drug with a manufacturer of a pre-10 scription drug with regards to the reimbursement policies 11 of the insurers of the manufacturer's drugs so long as no 12 one single wholesale acquisition price is jointly determined 13 between the insurance issuers or their designated agents.

14 SEC. 3. DEFINITIONS.

1

15 For purposes of this Act:

16 (1) ANTITRUST LAWS.—The term "antitrust 17 laws" has the meaning given it in subsection (a) of 18 the 1st section of the Clayton Act (15 U.S.C. 12(a)), 19 except that such term includes section 5 of the Fed-20 eral Trade Commission Act (15 U.S.C. 45) to the 21 extent such section 5 applies to unfair methods of 22 competition.

(2) HEALTH INSURANCE ISSUER.—The term
"health insurance issuer" means an insurance company, insurance service, or insurance organization
(including a health maintenance organization, as de-

1	
1	fined in paragraph (3)) which is licensed to engage
2	in the business of insurance in a State and which is
3	subject to State law which regulates insurance (with-
4	in the meaning of section $514(b)(2)$ of the Employee
5	Retirement Income Security Act of 1974 (29 U.S.C.
6	1144(b)(2))). Such term does not include a group
7	health plan.
8	(3) Health maintenance organization.—
9	The term "health maintenance organization"
10	means—
11	(A) a federally qualified health mainte-
12	nance organization (as defined in section
13	300e(a) of title 42 of the Code of Federal Reg-
14	ulations),
15	(B) an organization recognized under State
16	law as a health maintenance organization, or
17	(C) a similar organization regulated under
18	State law for solvency in the same manner and
19	to the same extent as such a health mainte-
20	nance organization.
21	(4) MANUFACTURER.—The term "manufac-
22	turer" means anyone who is engaged in manufac-
23	turing, preparing, propagating, compounding, proc-
24	essing, packaging, repackaging, or labeling of a pre-
25	scription drug.

(5) PRESCRIPTION DRUG.—The term "prescrip tion drug" means any human drug required by Fed eral law or regulation to be dispensed only by a pre scription, including finished dosage forms and active
 ingredients subject to section 503(b) of the Federal
 Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)).
 SEC. 4. EFFECTIVE DATE.

8 This Act shall take effect on the date of the enact-9 ment of this Act but shall not apply with respect to con-10 duct that occurs before such date.

0